<SEC-DOCUMENT>0001193125-14-377241.txt : 20141021
<SEC-HEADER>0001193125-14-377241.hdr.sgml : 20141021
<ACCEPTANCE-DATETIME>20141021140455
ACCESSION NUMBER:		0001193125-14-377241
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141021
FILED AS OF DATE:		20141021
DATE AS OF CHANGE:		20141021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		141165522

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d807925d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated October 21, 2014 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Translation of Registrant&#146;s Name) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Level 7, 151 Macquarie Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sydney, 2000 New South Wales, Australia
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form <FONT
STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: October 21, 2014 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prima BioMed Ltd</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Marc Voigt </FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marc Voigt </FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:75pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima Biomed Conference Call &amp; Webcast to Discuss Acquisition of Immutep</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d807925dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g807925imag001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21&nbsp;October 2014 </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED
CONFERENCE CALL&nbsp;&amp; WEBCAST TO DISCUSS ACQUISITION OF IMMUTEP </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;
or &#147;the Company&#148;) advises that the Company will host a shareholder conference call and webcast to discuss the Company&#146;s recent acquisition of French biopharmaceutical company Immutep SA (&#147;Immutep&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 2&nbsp;October 2014, Prima announced that it has reached an agreement to acquire Immutep for a consideration of up to US$28M (&#147;Acquisition&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s Chairman, Lucy Turnbull, Chief Executive Officer, Marc Voigt and Chief Technical Officer, Sharron Gargosky along with Professor
Fr&eacute;d&eacute;ric Triebel, founder of Immutep and Prima&#146;s Chief Scientific Officer designate, will discuss the key aspects of the Acquisition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast and Conference Call Details: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call
and webcast is scheduled for Friday, 24&nbsp;October 2014 at 8.00am Australian Eastern Standard Time. This corresponds to 5.00pm Eastern Daylight Time in the US. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call dial-in numbers and conference ID are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia&nbsp;Toll&nbsp;Free</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">1800 908 299</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia Local</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">+61&nbsp;2&nbsp;9007&nbsp;8048</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canada/USA</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">1 855 624 0077</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Germany</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">0800 183 0918</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conference ID</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">289311</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An audio webcast will be available via <U>http://www.media-server.com/m/go/Prima-Biomed-Oct-2014</U>. Before accessing the
webcast, it is recommended to click on the link and then on &#147;test your system configuration.&#148; A replay and a transcript of the conference call will also be available through Prima&#146;s website following the live event at
<U>www.primabiomed.com.au.</U> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated
to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima&#146;s lead product is CVac&#153;, an autologous dendritic cell-based product currently in clinical
trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
biopharmaceutical company developing immunotherapeutics in oncology. Products include a T cell immunostimulatory factor (APC activator) IMP321 for cancer chemoimmunotherapy and a therapeutic antibody for immune response modulation in cancer. The
Company&#146;s technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product IMP321 (a LAG-3Ig fusion protein) works by binding to a receptor on antigen presenting cells (APC&#146;s) such as dendritic cells
to activate them. The APC&#146;s are important for showing cancer antigens to T cells and activating them to destroy cancer cells. IMP321 is a first-in-class APC activator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients, licensed to CoStim
(Novartis) and IMP731, a depleting antibody that removes T cells involved in autoimmunity, licensed to GSK. In addition, there is the potential for a number of other products coming out of the company&#146;s research efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USA
Investor/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Holdsworth, ProActive Capital </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1
(646)&nbsp;862 4607; adamh@proactivecapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422
534 755; mgregorowski@citadelpr.com.au </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Europe Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Axel M&uuml;hlhaus, edicto GmbH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+49 (0)&nbsp;69
905505-52; amuehlhaus@edicto.de </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd,</B> Level 7, 151 Macquarie Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g807925imag001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g807925imag001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"$`L8#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBHC-@\CWZ]J=@):*C\X9IKW*H
M3D<`=?6D"UV)J*C67=C`_#/2I*`"BBBG8`HHHI`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%.P!1112`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBJ]Y,EK#)-*#LBC9FQZ`9H`\)_:8_:>7X/2Z3X5\!V$?B?XF>+
M91;Z#H0?@%N/.FQRL8Y/J<&NT\)6%Q\,_!$^H_$CQ`^H:FR_;-;U*8A8DDP-
MR1(.$B7HH].O-?G/^QOXT?\`:)_X*'^(?'7B=\R6-I?3:7`6^6*-"(8E`/3:
MA)X[DU]__M3>&]4\3?!;7K+P\LDMSMC<PQYS*BN"RCU.*FM4=.FY1U:1VY=A
M88G&4J$Y<L922;[)NU_D>8>(OV]_#.FWSP>']#U'6H58K]I,BPJWN`<DUV/P
ML_:E\)?&&\;0VCNM'U.Y0A+:Y<8F'?8X_B_6OSIE1X9GBE1XY8W(='7:RMW!
M'8UV_P`%?".M>,OB5H4'AF":6:TOXIIID)`MXE;+,S=N!C%?(4LZQDL0HRV;
M/Z`S?PRX>HY/*M&3A*,6^=R?Y/1W/J[5/V@KG]F'XP:9X%^,EX]QX%\4#/A3
MQ1<N7DM'7A[6[?\`BP2-K]<$9KZJM9S.@<,K*RAE(Z$'H:^-?^"I'ARSU+]E
M*\O+U$-UHFK6DUM*P^96+;&"GJ,@\_2NR_X)S_%+4_BI^S+H-YXFN9+W4](F
MFTN:>0Y:182/+8^IV,HSWVU]GOJ?SD?4%)FO@7_@K/\`$#Q3X!\)?#^?P)XB
MUGP]+>:G<1W#Z==M`95$8(#$=0#S7BWQ<\"?M"_LI_#_`$+XI^'_`(U:QXET
MB<6LEW9WT[D1M,@95:-R5=3RIZ&F!^LE(3CUK\H?VR/VJ/&'CO\`9U^"/CKP
MAK.K>$+WQ))?QZI%IEX\*O-#M5L$')7<"0.V:A^,OP>^/_P`^#NE_%?0/CQX
MAU:R\BUN;JTN;N2.2+SE4J%#$K*,L!MQG'K2L!^L@.?6EK\^/B;^T1XN^)/_
M``3/7XAK?WF@^*I9H+>>^T^0V[.\=SY;2*1T#`9QTY->W?L'^,M0UC]D#PQX
MA\::M>ZI>+!>S7E]?3F61UCGD)+,>3A12L!],9H'-?EW^P+^U9XC^(O[6_C#
M2O%FLZE?:-XR2\GTJQN;II(K%XI2Z)&IX4&/(X]*UOAG^UIJ^O?\%*M9T1-?
MU"[\%ZS<3Z):6#3DVT,D2821$S@,7C89]Z+`?I?29S4$MU%;6KR7,B1QPH6D
M9C@*`,DD_05^*/QE_:;^,'CSXD^,_B=X$\0:]8^!?"^O6]I'!9WTD=H$WD0J
M4!P2XC);_>HL!^VU%<?\(_'UI\4OAMX<\6Z4P-OK^FPW04'.QF7YU^H;(_"N
MPHL`A-&:_)SX[:E\1/B+_P`%"-2^&/A3XE>*?">G:M=QQ0_8[R3RK7%L')$8
M('4?K4>H^./C9^Q=^U'X5\'^(/B5>_$+3/$4EOOM;R9YA)!++L.8V):.4=00
M:+`?K/FEK\YOVW/B3XL\,?MI_"'1?#7B36M*TG419?;;"UO&CAN-UT00Z@X.
M5X->A_MX?M0^,OA[XB\,?"CX$1K_`,)UXXX%X#N>R1WV)L!X#,<G<?NA<T6`
M^UJ*_,GQQ^SO^U5\!/!1^(^D_&74/%&H:#";[6-$DN994\M.6"A_EE`&<C`X
MSBOL3]DC]H:/]I+X)Z?XPN8(K'4HI'M=6M87)2*>/[Q7/.T@AA]:+`>XYHS7
MY9?LM_M6^(O&_P"W]KEIXC\1ZE/X:\2W6H6.E:6]TQMH2G^I"(3@$B/.?4FN
MEUK]KS4;O_@I;I&@6NM7\/@O3;C_`(1R6R2<B"XN'1@TK)G!/FLH#>@HL!^E
M&<TM?G7_`,%5O'WB_P`'ZY\+;/P)XHUOPX-6FNH;EM-NWA\SYHPI;!&[&3Q6
MUI_[`?Q@<6EU)^TIXR=#LF:(B7!'!*_ZSI18#[Y!R**_.3_@JMX^\7>`9_AA
M;>!?%.N:!)J`N(KJ73[MH?.(,2AG`/)Y)K,\9?LJ_M/?"SPQ!XQ^%7QMU_Q9
M):6PO;G2[FYDC=T"[R$5RRR<?P\9J@/TOHKX^_8#_;+U#]IC0M8T7X@6UK9^
M,_#&QYVMQL6^@)*B78?NL&&&4<9(]:^P%.5!'0BIL`M%%%(`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`JM?1"XMY(7!*3(R/]""#5FFL@;KG\*`/PMT#6=7_`&#OVSKB
M7Q!:S7-OHFH3).BM@WNFW!)$BGN=I##W4U^U7@GQ_H/Q3\*V.N>!]3M=5TK4
MHA)#<P.'`Z$JV/NL.A!Y!KYU_;R_8V@_:8\(1ZCX46UM/'.@(3I]PZA?ML7>
MWD;T/52>A]C7YH?`']IGXD_L1_$"^TF_L+M--CN2NM^%M14Q*[]/,0D?(W'#
M#@XYR*I(32:LS]H==^`G@/Q/>-=Z]X7TFZNY#F27R=C.?4E<9K8\.>`?#O@.
MWDC\+Z38Z5'(`7^S1;=^/[QZFO-OA)^V)\-_B[\-KCQAI7B&QTRSTJ-3K,>H
MOY!T^3;N*,6X;C."N<XXKX2_;._X*:7/C6.[\'?L]7$^G:,Q\N^\2CY);Q<$
M%(5(RB'NW4]L5"I4U+F45<ZJF,Q-2E[*=23CV;=B7_@J5^U7IWC!K3X3^`;Z
MVU&ST^Z6Z\07D#AU,Z_ZN!6'#8R6;'?`KZV_X)O_``PU3X7_`+,6AV_B:UDL
MM2URYGU22"48>..4CRP1V)50V/\`:KXI_P""??[!UU\3]9L?B'\8]/EM_"-I
M-YVFZ9=Q%7UB3G$C#.1$K`'G[Q'I7Z[0VZ6ZJL0"HB[54#``K2YS'YT_\%EB
M?^$,^&V"/^0O=<'U\H5R\/[%W[3'[16@>'--^-GQ+TJT\"QVUM/;VMJXF(C"
M+Y>(E107"G&6/%?4G[</[(^J?M8:-X5L=#\0V&@'P]>RW,C75J\WF[U"@#:1
MC&*^B/"ND/H7A?2-+FD65].L(;9I%&`Y1`I(],XH`_+_`/X*B?#71_@[\(?@
MGX0\*1&+2M!>]AA#')D.R/=(Q[LS$D_6O)OVFOA;\3_A-X3^&^J_&7QCJ?Q&
M^'>K_9Y(]+%[+`D6(P_V<@=#Y>=K#T-?H+^W%^R#JO[6MAX0M=$\0V'A]O#M
MQ<RR-=6SS><)%0`#:1C&T]?6NS^-W[-=O\9OV=%^&FL75M'?6NGVL5AJ;Q$K
M;W,*JJRA0<X(##'H:`/#_P!L5_"\G_!-Y)?AE9PZ?X8GM=,ETRUBZ11-*AVD
M^N<Y)[YKS_PI\5)/A+_P27MM2L)`FHZG;W.EV1'!WW%S(A/X(7/X5ZW!^Q'X
MLD_8UOO@AK7C;3;VY:_673]5-I)Y=M;B59/**DY."&QSWK#\1?L`^*M>_9_^
M&OPJ;QMHZ:7X.U66_P!6D%A(?[1+2EU51GY<*[CGUH`^0?%^@2?L9S_L\?$C
M1=)(O=3\*S3:FC94W-PX<Y8]B(YX^/\`9J"3X?3_``%^$_P+^.4T$K:UK7C6
M74]4N)%P?L[.&B4_[)5';WW&OT<_:_\`V3[;]IKX9:%X8LK^VT2]\/W\4]G>
M26YE6.)5V21A01]Y<8]P*N?M&_LMVWQO_9UB^&&C7MMI+::MF--O)H3(D!@`
M7)0'/*[A^-`'/?MY_'ZS^%G[,.IZAI<V^_\`&]N-/T;RWP3Y\>6<8[",L<^N
M*^#_`(*?&WX:>#/V0?$WPM\9>%?&VH:UXJ-S=37=KHQ>*.X(`MF5NIV;5.?K
M7UQ\9OV$O%_QNC^%ND>*?'&E#PQX`TVVM;RP2RD+7TJ[1-(&S\I9$51GI7V3
M9>'=-TBP@M;"QM(H+:)(HD\E<*J@!1T]`*`/@#_@D5\:EO?!OB+X9>(+^1M2
MT2Y^WZ3:S9WBV?B5%SV5QG';>:_10'-?%OAW]A76/`'[7UQ\8/`7BK3+/1KZ
M]EGO-#ELWWM'.N)HPX.`-V&''6OLZW),(SUYH`_(+XY>!+WXE?\`!3Z\\-:)
MXBU'PI?:K>1+%K&GY\^T(M,Y7!'7&.HZU>^)?@.^_8,_:+\(^)?B%<:=\8+7
MQ(Z>5J?B`.U_8NCJ&D1=[890P*DY'6OH/XU?\$_?'7Q`_:.U/XL?#OXD:?X1
MU"XFCDL6%C(\]J5B$9.X''//;O5/0/\`@F=XA\4_$G2?%_[2'Q5O?'TFDRI(
MEK]F8><J-N6-G=CA,]0HH`\Y_;IG2Z_;D^!L\.3'/'I\B$C!*M=9&??FMWXU
MN/#7_!6+P!J?BJ1(-,U"RM4L)YSM0-Y4L8`/KYAQ]37M_P"T+^QEJOQG_:"\
M!_$33/$FGZ98^#!;B33Y;1W><13>9A6!P../PK=_;%_9`T_]J'2-+OM,U-O#
MWC/PVYDT?554LHY#>7(!R!N`8,.010![7\4-=T[1OAIXHO\`6IHH-/MM'NGG
MDFX55\I@<U^9O[(/CC4OA!^P+\;?&5J6MENM0>#16;@><\:Q?+[C>/RKO-2_
M9._:[^+-E_PAGQA^*>DIX*EQ%>S02K+)=1`YP56-6<\#ACBO9/C!^PO_`,)7
M^SCX:^#_`,*M>M_#.CZ+J,=WJ$]Y`\S:B0#N+;2.6<[O3@"@#X%N_A-JW[,/
MPR^`WQR%N\NJ7&JS76H0L=I=7;S+;)ZY,8;\ZMI\,=2TC]FRT_:)\26QBUZ]
M^)4.JQ3,OSO9%SDCT4R9(^@K](_VD_V5H_CM^SUI_P`-=-U2WT>71S9&QO9+
M<NL7D*$/R@YP5S5OXI?LM6WCS]E-/@YHVH1:>MKI=I:6M]+"75)(&5MY4'/S
M%3_WU0!\<?\`!5G6(/&T?P/U/1K@"UUR&6>UN8SG:LODE6!_']*]R\`_L,_$
M/PYX@\/:W?\`[1/CK5+#3[B"ZETN='$=RBD,8F_>GY2!MZ=#6-\7O^">7BKX
MI?"SX2^%8?'.DV&H_#.QDMGOGLI'%SEE\LH,Y7`4=:EM_P!D+]IRU>)'_:5N
M'MXMNZ(6DGS("/EZ\9`Q0!YM_P`%ACG6?A'TYGN?_0XJ_0>;Q/I7@_X?6^L>
M)[N&QTS3M,CGN;B=PJ1HL0)))[^U?.?[:?[&FN?M5#P4VB^*-.T"3PNL@>2Y
MM7F,S.$P1@C&"E>7>(_^"=/Q=^*%C;Z/\8_V@=1UG0+=E*6,%E(5`7@?*6"D
M@=,@T`>=_P#!,]H_&'[7'Q9\7>&;26+PY=07;PR;-JHL]V'B3'J5&<>U?J:O
MW1]*\I_9U_9P\'_LW>"O[!^']J^ZX=9-1U"=MT]_*!C?(>@XX`'`KU>DP"BB
MBI`****`/E_1OVZ_!MVRC5]-U[3??8LP_P#'379:?^UU\,M1QG7Y;8D=+BT=
M?Z5^<XSVYIW7J.E?%QXAQ5KV1_0E;PKR::]R4H_-/\S].;#]H/X>W[*+?Q?H
MX9NBR3[/YUUFG^-]#U5`VFZUI-T#T\J\0Y_6OR:VJ>P_&I(&:!]T#O&?5&*G
M\Q6U/B2K]J"/(K>$]!_PL4UZI/\`(_75+R.;`C=&ST*MFGEB1R?UQ7Y+QZ[J
M2`!-3U-0.@6[D`_G5[3O&VOZ5/YMCK.I(<\YN6;/X$FNF/$L+V=,\Z?A'B+.
MV*3]8M?D?JT"2!AN*49!R6&*_-C2/VDOB-HRA;+Q'*8UZ++!&XQ^5=39?MD?
M$>U(-Q/I5T!U#V>,_D:ZH\1X5[IH\BOX89U3^%PDO7_,_0`-N_B%-.=_48^M
M?$-G^W)XNB*_;-#T.X`ZX:1"?R-=1IG[=<9(_M;PM-&>YMKL,/P#"MXYY@I;
MR/*K\`9_2U]@GZ-,^N2W(Q4E?-^G?MN>#+C;]NTW78'XSB)'`_)JW[/]L?X<
M73A9+S4K?/>6Q;`_$9K>.8X5[31YM3A?.*:N\-+Y*_Y7/<:*\WTO]HKX=ZLJ
MFV\4:>A;^&8F,_J*W[7XH>$[['V/Q#I$V>FV[3_&NB->E+:2/,JX#%TOXE*2
M]8O_`".IHK.M_$&G73;;:]M)3_L3*?ZU<6X1S\AW>X.:T4HO9G,X26Z):*B^
MT#)X(QZB@W"@`\\U2U(NB6BH$NU=MH!!QGFI/,7U%%F--/8?13=XQFFF9119
M@245%YZ^AI1,O?(HLQ73V)**9YJYX-!D'N:+#'T4P2@BCS,G@&@5Q]%)FEI#
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`$*@]0/RKY=_;9_9B^&GQC^'^J^)OB3<#PUJ7ARP>6+Q1#'NDMHE^8JZ#
M_6KG@*>>>*^HZ^-O^"J$VMI^RM>CP^)1;G6;3^U&3^&WW'J?[N_;^E`'Y+_%
M'XE1>(X[7P[X/M/[$\$:*Y_L[3X\J;ER`K75P?XYGQDYX7.T=*^LO^"8W[-'
MPZ^,NH:QXC\?7']LZQX8N8Q;>')5V1(#RER_.9!D$;>@(YZU]5?L1_L<>%?"
MW[-H_P"$TLK?6=3^(^FK/JDLL8)MH)4_=Q1$C*E5.<CG<?:OG_\`8O\`A->_
M`W_@H=XM\$Z=-<7.E:1I5V#*QR7MF"/`7(XSDJ/<CWJP/U/M[>.W@CCAC2-(
MU`554`*!TP.U34B_=&.F*6I8"4M%%-`)M'H/RH(!ZTM%,!-H'8?E1@>@I:*`
M$P/04;1Z#\J6B@!-H]!01GKS2T4`-V+G.!GZ4H&!Q2T4`)@#L*,4M%`"8HVC
M/0?E2T4`)@4;1C&!^5+10`F!Z"@`#H!S2T4`)@#H.M&!Z"EHH`3`]!2T44`(
M!CI2T44F`4445(!1110!^<=U^Q[\3[7+1Z38W`'_`#QOT)_7%<CKOP,^('AP
M$ZOX4U8`'&Z"'S@?Q7-?J3M'H.*0QJ>H%?//AO#?9DS]-P_BGF\/XL(2^]/\
MW^1^1-SHNI6;LM[IVH6Q4\K+:NI'YBJG*G!^7!P0>M?KU/IUK=?\?5M!-_UT
MC#?S%8.J_#3PIK*D:GX<T6YW9SYEDG^%<\^&4]IGM4/%Q_\`+W"KY2O^:/RG
M5L'VJ3^M?I+JO[-'PXU13YOA/38B>]N&B/\`XZ:X[6_V+/`&I'=IZZMI3D<&
M&Y+J/P:N*?#>(C\#N>K0\4\KJ.U6G-?)/]3X,6G9)K[!O_V#-/9F.E^*K],]
M!/:*<?B"*Y?5_P!ACQ';9_L?7-,NR/NB:-HOU&:YIY'C8_8/7H^(.05]%6MZ
MIH^:ATIZ8/!KV*__`&1OB58,0FE6=VH_B@O5.?P/-<W>_`7X@Z46^U>$M5..
M<Q)O!_*N66"Q--ZP9Z]'B3*:W\/$1?S1PW0>GTIR$+PH`'M5_4/#NK:3*5U7
M2]1LR.HGMG7'YBJ`!0DR!DQ_>&*Y9PE'XDST(8C#U=8M/T:9/LW@<<^M2(H7
MD#!/6HU;CCD'TJ1#Z\?6G%V6FA;4)?$]/7]"Q%/+$P:*61&]5<BM>U\9:_8L
M/L>MZM"!T"7C@?EFL13G!'(J0</FJ56I%7C+\3FK87#S^*"EZV_R.PM/BOXS
MM2/(\4:TH'_3R3_.N@T[]H?XA:<04\1W,ZCC$\2./Y5YHIXJ<#`%;+%XB.O.
MSSJN3X"JK3HP:]$>VZ?^UIXULQ^_32KDGC,EL5)_(UMP?MB^(P,7&B:1*P[A
MW7^M?/*GFIAG/%;QSC&QVFSRJ_!^237^[17HO^"?3&G_`+9UXH7^TO#4!`^\
M8+H_U%=-IW[87AZ;']HZ1JELQZ^7MD`_6OD:/C.*F7[F.U;PS[&K=GE5N`\E
MEM!Q]&_U/LZW_:M\%3_?;4X?]^V_P-:=M^TIX"N`/,U1X2?^>ELX_I7Q%'T&
M*GR3ZFMX\1XI;I,X)^'>5OX9R7S7^1]WV/QJ\%:B1]C\0:?DG^-]O\ZZ"U\9
M:/>`&UU739%(X(N4Y_6OSU7&,GDU*@P1Z^M=,>):KW@CS*GAQA[^Y7:^29^B
M"ZQ:R_ZNZLW],3*?ZU*EXCD!7C.?0YK\\XII5(V22K]'(K2M-;U*T/\`HNH7
ML1'39.PQ^M=,>(XVUIG#5\.9KX,1_P"2_P#!/T#`)[XIZ\9S7PC:_$+Q-;$>
M5K^JJ!ZW+'^M:EO\7/&,!_=^(M1_%PW\Q51XBH/[+..7A]C%M4C\[H^W*0'-
M?'%I\<?&UL`3K;RGTEA1OZ5NV?[1OBZ,CS&TV<#^];XS^1K=9]A7W..IP/F<
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M/DZ6]P-LD<*YV1N1U"C"[NI`&>:S_AO\%]%\":[XH\2Q[KWQ/XSO1<ZQJ4H^
M9PH"QPI_=B0`87ZD\UWY.?O#\UI58*,*`!^55N)21*!@`>E+47F?YS1O/JO_
M`'U18=R6BHMY]1^='F>X_.FD*Y+147F>X_.CS/<?G3L%WV):*B\SW'YTGF^X
M_.DQW9-14/F'U'YTGF'U'YT!=D]%0;R?XC09&`XRWM2;#F1/15?S&/\`"P_&
M@2MTPQ-3S?U<+EBBJXD8GH1]33MQ[M5*["Y-15<[V/RR8_6C]X#]\'\*JP7+
M%%0>:W>E$I[8/U.*5F":9-14/F,?3\Z:LV/O-Q[B@+HL454DO;>/_67$2#_:
MD`JI-XATN#_6ZE8H/]JY4?UJ/:1[EQA.6R-:BN.U+XK>$-)5FU'Q/HMOMZAK
MY,_EFN4U']J7X9::VV;Q=8.WI$KR?R%9RQ5".\T==/+,=4?N49/Y/_(]<HKP
MBZ_;*^&5H3LUJ[N?^N-E(W]*YC5_V[_!=F7&EZ=KFH$'Y<(L0/\`WT:PGF.%
MCO-'HT>%\YK.T,+/[CZ>HKXOU'_@H/+N*Z3X-<#^%KB_ZCZ!:YS4?V^/&,Y/
M]FZ)HEJ.V\O(1^HKFEG.#BOC/8I>'G$,VDZ'+ZM+]3[R+`'FBOS7UG]L/XHZ
MI.9(]<MK!,\1VMHJ@?GDT5ROB+")]3U(^%>=M7<H+_M[_@'Z4T445[Q^:A2<
MYYZ4M%`#&4X^7&:;L8]2*EHIO45B+RCGG^=$D18<`?G4M%%PL1+$0.:##D]:
MEHHNP:3W*<NGQS`B:*&0'J&0'^=9=[X$T+4B1J&CZ5.K#G?:(3_*N@HJ'"#W
M2-(5:D'>,FO1V/-]2_9Z\`:I*7NO"VF$GJ44H?T-8=_^R?\`#N]4^5I$MJYZ
M-#=R#'X9KV2BL)X/#SW@CT*.=9E1_AUYK_MY_P"9\U7_`.Q#X?F!.G:_JUJV
M<J'590/;M7/7_P"P_=*W_$N\40G/_/>T.?T-?6U(<=ZYIY1@YOX#U:7&N?4E
M:.(?W+_(^)M6_8X\8V`)TZ]TB_"]`)&B/ZBN6N?V<OB):9#>'Y)\'K#.C?UK
M[_9<GUJ$Q@'C(KGGP_@WM='I4?$;.(:2Y9>J_P`C\[KOX0^-=.R;OPSJR*O5
MA!N'Z5A7.D7UDS+?65[;E>OF6[+C\Q7Z7&/)&<\>HJ*XL;>X!%S#!*".CQAO
MYUR3X:IOX9GJ4O$_$+^)0B_FT?F?&R]C^?%3IRN,C/IFOT/N?`'A[4"3>:+I
M\P;^]:IC^59%_P#`OP+J$967PWIRD]XT*?R-<T^&*OV9H]"GXEX:3_>X>2]&
MF?!<7&<U/&1@C()]J^T+G]F'P'<9V:?<6Q/_`#QN6'\\UA:C^R1X7G#?V??Z
MO:GL2ZR#\<BN:7#N*CM9G=3\0LJGNI1]5?\`(^3P.:G4]*^AKO\`9`D!8Z?X
ME&,<+-:?U!K*NOV3M?AXM-7TV<]@RLI-8/)\9%?`=U/C')JG_+ZWJFCQ:,XJ
M56&?K7HNH_L[>-=.)$5E;78'>&X&?R-8T_PC\8V@S/X?OL#N@#Y_(UC+!8F.
MC@SNCGV65%[M:/WG,1#@U.G\JOS>$-<LL_:=(U*+'4M;-C^549(9;5ML\<L1
M[[T*_P`ZR]A4BOA?W'5#$T9Q]V::\FG^3)0>!5A.F?6JB8<91UQZ@YJ>-\XP
M0?H:E7Z@VUK?^OQ+*-@\5.C<\U60583[U-&32;N68V'`J>-AOQ[540Y_"IXV
MZ5HHKL935V7%'-2J=IJO&_8U(9*T3L9RII:Q+<;]`:D)]*IH_`([T\.35IKJ
M1RNQ8.#UX-)O/8E2.AS4.^F[^:KG\R/8I[HE-Q(IRDTH)/57(ICZC>(PV7=T
M![3L/ZU`7&3]:9)(,YJ/:S6S'+#T[?"ON19_X2#4X#^[U&_4CIMN7_QJ0>-_
M$,./*UK4E'<?:":RG?YOK5>0]J3Q%9;38HX.A+XH+[D="/B7XIA'[K7=1'UE
MS2_\+9\7(,KKMYGWP?Z5RTDF,#UJ%CNIK%XCI4?WB>58%ZNC'[D=F/C3XS09
M77)<CUB4_P!*1?CSXWB;_D+JW^];(?Z5PSC;D`FH7Z4+'8G_`)^,K^P\L>GL
M(_<>C+^T/XU3EKZT?ZVB_P!*GC_:5\80C+'3)/K;8_D:\L=N<5"SY&/2I>8X
MI/XV2^'<JEO0C]UOR/7T_:D\4QG][9Z3(/\`KFP_K4R_M8:]'CS=&TM_H[BO
M$WX-0R')%4LTQ:^VQ+A+)G_RX7WO_,]Y3]KG4U'[SPY8-CTNG']*</VO[U#S
MX;M1]+MO\*^?SW%0OUJ_[8QJ7QCCP?DK_P"7/XR_S/H<_MAW0^]X;A_\"S_\
M30O[8LO_`"T\,H3[7?\`]:OG*1N<>E,8\9J%G6-_G#_4K)'I['\9?YGTB?VR
M@OWO##?A>#_"D_X;,B_Z%:0_]O@_PKYHDP>U1D8%4L\QJ^T-\"Y(]J7XO_,^
MFC^V?$O7PK-^%ZO^%-/[:5NO7PI/_P"!J_X5\Q,<FH)#EOI5+/L9_,+_`%"R
M1_\`+I_>_P#,^HC^VQ;#C_A%;G_P-7_"F_\`#;5N.OA2Y_\``U?\*^6W/3BH
MCUH_M[&_S&K\/\C2_A/_`,"9]3G]MZU4\>$[G/\`U^K_`(4P_MP6_P#T*5Q_
MX'+_`/$U\JOG=Q3&;G'%)Y[C?YBH^'N1M?PG_P"!,^JF_;C@'`\(S_C?+_\`
M$TQOVY80./"$WXWJ_P#Q-?*A&<FHW8@&C^W<;_,:KP^R)?\`+I_^!/\`S/JI
MOVZ\#Y/"3CZWP_\`B:A/[=LJC*>$US[WO_V-?*C-R::.GXTGGF-_F-H\`Y!;
M^#_Y-+_,^IW_`&\+P_=\)0?C?-_\35>3]O#4\'9X2L?;=?/_`/$U\O'H:A<X
M%3_;6._Y^?D;1X"R"W\#_P`FE_F?34W[=.ON#Y7A;28SV+74C8_2LV?]N7QD
MY/V71]"B^JNW]:^<CS1]T5+SC&O>HS>/`O#^_P!77WR_S/>+K]M/XB3.3!_8
MUN#_`'+3./S-9ES^V%\39R=FKV4/^Y8)_6O&"<U$>I^M9O,\7_S\9VT^$,CA
MMAH_-7_,]9G_`&J?B=,"6\3.OLEI$/\`V6LVX_:1^)-WS+XLU%>WR!5_D*\W
M;[II@Z&L_KV*>]1_>=4>&\HCMAH?^`Q_R.[N/CO\0KA3O\7ZY@^ESM_D*Q+W
MXD^*]0_X_/$VO29];Z3^A%<^.E1T?6Z\MYL[*>3Y?37N4(K_`+=7^1HR^(]6
MG'[_`%?593_MWDC?S:J<EU/,?WUQ,_\`O2$_UJ*BLW.;=W)G5'"T(JT8)?)?
MY#'5>XR>I)YIK$8XI[=?PJ)NE9)WW.I145H'%`I**.1+5$W%STI0,YYIM(7*
M=.]-R:8XKM_7ZC#D44H.:*@U3[H_9.BBBOU4_B@****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`$Q1M'I2T4;`)@4%0>H%+10`@`'048%+10`FT>E&T>@I:
M*`L)@>E(44G)49]<4ZBG<!GE+Z4OEKC``Q3J*!60P1(!@`8]*J7.B:?>#%W9
M6LW_`%TA5OYBKU%2XI[E1;C\.ASEQ\/_``Y=$^?H6E,O;_1E'\A6-=_!GPA>
M+A]#M8S_`'H\I_(UWE-`]:REAZ4MX)G33QV)I_!4:^;/+;G]GSPBYR+:ZBS_
M`,\KAN/SS6?<_LX>'I`397FIV[>I</\`TKV%D..*3RL]364L!A9K6FCKAGV9
MPTC6E]YX+<_LSO\`-]AUU@.PEM\_R-9UQ^SCKL2;H-0L)LGH59*^C0N.@I&4
MGMGZFL)91A'M$[*?%>;15O:7^1\R3_`CQ/;*?+6RE(Z;)SG]165<_"WQ39C$
MND3RX[Q,&S^5?6`7CD8_&FF(EB<G\ZS>2X9K1M'53XSS*&Z4CY"?P;KT`S+H
M^I(1V^SDU4ETG4K8?Z1IU['CJ6MV']*^R/)QT/--:#<,,J.#UW#-8/(8?SG9
M3XYQ"^*DOO9\6O*T9Q(K(1V8$4T2!NC`_0U]C7'AZQN\FXL;&4GKOMU/]*SK
MCX=>';H$3:+IQSU*Q!?Y5B\AETD=T..X->_1?R:/D9I1G`YJ.0G'6OJV?X.^
M%)E_Y!$"D]U9A_6LBY_9_P#"]PQ*PW,.?[EPU8RR.O;1HZZ?&V"?Q0DON9\Q
M$G/-1N_-?2$_[-N@N#Y%Y?Q9Z?.&_F*R[C]F&V=3]FUNY0]@\*D?H:YIY+BX
MZV3.^CQCE4G[TFO5/]#Y[;Y\GK4+9"GK7MEY^S!K$;?Z#J]C*/\`;C9369-^
MS5XL3)BNM+E]O.9?Z5SO*\6M?9GH0XHRB?\`R]_3\SQ^1CV)J/DCG->FWG[/
MGC.W!Q:6<H_Z9W`_K7/WWP@\96(/F:%=2#/6(JX_0UD\%B%]A_<>A1SW+9Z1
MJQ^]'&,<GDU#)\IK>G\#^([?/GZ%JJ8_Z=6/]*SKG1-1A!\[3[V/'7=;L/Z5
MR3HU$_A9Z-'&X:6U1?>C,=LG%1/4T\,L)_>QR(?]M"/YU5:0,>HX]ZRY7V.Z
M,HR^%H:QXJ`\]:F<C'WA^=0D@'K43:V-X^1#(?FJ-CR!FI9!@9XQ]:A<$X8<
MBH*:&O\`?'IBH2>#FGYZGTJ)SD57*S5/083DG%5V[U.>!4![TK&B?F,DZBH>
MYJ9^2,5`V1R*3T.E(:W6HSZFGGU-1D\4%H9_C43]_K4I.,5#)T_&@N.NQ">I
MI.,4K=3494D\8H-=A,Y'6HGZ4\G:>:8_2@J(8&SI40P5.[&:DW#;BHB.:9K%
MI""HSU/UJ6HS]XT,H:WW33!T-.+'HU(>E""_01>E1T\,!UIE5'<T8448S1BJ
M$-;K^%1-TJ5^#GM49K-;FCV&T48]Q16ES,!UI)!TI1UHD[5$MRX[#****DH_
M9.BBBOU4_BH****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@"+RP?6FO'C&<=:FVCTHP*">5%8H#_#GWI#`K##1QD>XJR44
M]12@8Z4U;JAK0SI]%L;M2MU96DH/9X5;^8K&O/AMX7O<_:_#VE2D]S;@?RKJ
ML48S4N%/^4UC6JQ^&37S9Y[-\#?`TQ8GP[8(6ZA`5_D:SKG]G+P'<@_\2?RV
M/0I.X_K7J>T>E($`/`K*>%P\MX(ZX9KCX?#6DO\`MYGB5Y^R?X*N>8SJMO[1
MW.1^H-9EQ^QYX7F;_1]4UF/CNR-C]*^@<"DVCTKGGEF$DK.FCLI\2YO3^'$2
M^^_YGS;=?L::448VGB+45('`>!#6!>?L;WA#?8/$=N?036Y_I7UEM!ZBF^4G
M]T5E_8N!M\!V0XRSR#NJ_P!Z3/C>Z_8Z\6*#]DU71)U'0DNG]*R9_P!D?Q['
MDQ#2)L?W;K&?S%?<`4+T`%&`:Q>08%N_*>A#Q!SN/VD_D?!$O[,'Q$0';I-O
M)_N7:?XUC:C^S]\0+`'S/#5Z_O$5?^1K]$-H]*;Y29SBLI\/8:6S:.FGXCYI
M%>]"#^37ZGYG7WPT\6V`(O/#>M1^O^B,?Y5D2^&-:@)$NC:LN/6RD_PK]23&
MI&"`133!&>J*?PKGEPU3>TV>A2\4,9'XZ$7\VC\J[C3;V$@2V5XG^_`P_I5*
M821\21NF#_$I%?J\UC;M]Z"(Y]4%4KKPQH]\I%YI>GS`]=]LI_I63X9_EJ'=
M3\5/Y\+]TO\`.+/RG+*<<@$GIFDR",#!_&OT[N_@_P""KYV:Z\+:+(7/)^R*
M,_E6+??LY?#:ZR9?".F`MU*!E_D:SEPQ46L9K\3NI>*F$_Y>4)1]+/\`-H_-
MEAS3).!7Z)3_`+*OPTGZ>'5B_P!R>0?UK,N/V0/AK*S8TV_CS_<O7'\ZR?#F
M*Z-?C_D==/Q4RIZ.G/[E_F?GX?:FDD]J^\KG]BGX?3)B%]<@)[I=YQ^8K)G_
M`&%/",A)M]<U^(=@S1M_[+42X=QB['H4O$W([>]S+_MT^(2^.HIF><U]H7'[
M!>C.Q^Q^)M37C_EI"A_E6;<?L#(0?L_B]U/8/9`_R:L7D>-_E.N'B1D$O^7C
M7_;K/CXG+&@]*^K;C]@/5AG[+XLL&/;S+-Q^H-8=]^PIXSB!%GK.ASD=/OIG
M\Q6;R?&K[!V0X\X?EK]82]4_\CYJ/44E>^W/[$WQ*C)\F/0YL?W;_;G\Q6;)
M^QU\4(_NZ1I[_34$J?[+QD?BIL[J?&.0U%[N*C]]OS/%!2DX%>NW/[)_Q0MQ
MSX<W_P#7*ZC;^M9-W^SA\2[3(D\(ZBX']PHW\C64\)B(O6#.NEQ-E#?NXF'_
M`($CS-FS3:[*Z^#?CFS)^U>$M?7'7;9,W\A6-<^"?$=F<77A_7(B.N^PD']*
MQ>&K+>+/0AFN`G\->#])+_,QL"FGK5J72-2A.)M.U%#_`+5I(/Z5$UK<1_ZR
MVN5_WH6']*E4YIZIFOUJA+X9I_-$0ZT2=J"=IY!4^],DD7CYA^=3)/=Z&D*D
M'HF%%-W`]"#^-%9W7=?>;:=T?LK1117ZL?Q2%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%5T`9FFNQ'0FBBH3U&,W'<*=G
M(YHHH;=Q60Y>E,?@$X&1116BV,[ZE<7#D=14D;EP=V#110_B-JFBT'8']T4_
M:,=!115&$9-O<:P"@$`<TY"3[?2BBCH=$4K7&%R,TF[S`0P&/I114V1"V9$]
MM"Y_>00O_O(#5:30M-G8F;3[%\_WK=#_`$HHK.4(WV!SDEHRO<^"?#T\9$VA
MZ0_?YK*,_P!*R+CX6>#;P$7/A;09/K8Q_P"%%%5&C3DM8K[BUC,3"24:C7HV
L9D_[/OPWO<//X,T$L>I6V"_RHHHK"6%H7^!?<COCFV8**M7G_P"!/_,__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
